JR九州ドラッグイレブン: Removal from Consolidation and Equity-Method Accounting
First written in FY2021-Q1. 2 of 4 entries say "Reframed", first in FY2023. Latest entry: FY2024-Q3.
1 other company's latest entry also says "Restated".
- FY2024-Q3RestatedAnnual report
「Drug Eleven Co., Ltd., previously an equity-method affiliate, was removed from the scope of equity-method application from the end of the first quarter of the consolidated fiscal year because all of the shares held were transferred on 31 May 2023.」
The transfer of all shares in Drug Eleven Co., Ltd. and its removal from the scope of equity-method application continue to be disclosed. - FY2024-Q1ReframedAnnual report
「Drug Eleven Co., Ltd., previously an equity-method affiliate, was removed from the scope of equity-method application from the end of the first quarter of the consolidated fiscal year because all of the shares held were transferred.」
Drug Eleven was also removed from the Company’s equity-method affiliates, ending the Company’s ownership relationship. - FY2023ReframedAnnual report
「In connection with this transfer, the target company will be removed from the Company’s equity-method affiliates.」
Drug Eleven was removed from the Company’s equity-method affiliates, moving toward the termination of the Company’s ownership relationship. - FY2021-Q1First statedAnnual report
「JR Kyushu Drug Eleven Co., Ltd., whose shares were partially transferred on 28 May 2020, was removed from the scope of consolidation at the end of the first quarter of the consolidated fiscal year. It was included in the scope of equity-method application from the same date.」
Following the partial transfer of shares, JR Kyushu Drug Eleven changed from a consolidated subsidiary to an equity-method affiliate.